In this multicenter , randomized , double-blind , placebo-controlled crossover study , subjects received placebo followed by ABT-089 ( 2 mg once daily [ QD ] , 5 mg QD , 15 mg QD , 40 mg QD , or 40 mg twice daily [ BID ] ) , or vice versa , in a 22 crossover design .
